DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider. Patients may self-inject DUPIXENT, or a caregiver may administer DUPIXENT, after training has been provided by a healthcare provider on proper subcutaneous injection technique. It is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use and full Prescribing Information. Patients should read the Instructions for Use prior to injecting.
Maintain long–term control of moderate-to-severe atopic dermatitis with DUPIXENT 300 mg Q2W
Q2W, once every 2 weeks.
DUPIXENT is a clear to slightly opalescent, colorless
to pale yellow solution available as:
DUPIXENT is available in cartons containing 2pre-filled syringes with needle shields, and each syringe is designed to deliver 300 mg of DUPIXENT in a 2 mL solution
Advise patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use) before the patient starts using DUPIXENT and each time the prescription is renewed as there may be new information they need to know.
Administration Instructions: Provide proper training to patients and/or caregivers on proper subcutaneous injection technique, including aseptic technique, and the preparation and administration of DUPIXENT prior to use.
Advise patients to follow sharps disposal recommendations [see Instructions for Use].
Hypersensitivity:Advise patients to discontinue DUPIXENT and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions.
Conjunctivitis and Keratitis:Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop.
Reduction in Corticosteroid Dosage: Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Comorbid Asthma:Advise patients with comorbid asthma not to adjust or stop their asthma treatment without talking to their physicians.